Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Figure 2

Serum calcitonin and CEA concentrations per patient over time. (a) Serum calcitonin over time for all patients, (b) close-up of figure (a) for patients 2, 5, and 6, (c) serum CEA for all patients, and (d) close-up of figure (c) for patients 1, 4, 5, 6, and 7.

(a)

(b)

(c)

(d)